CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy

References

• Nadler L.M., Anderson K.C., Marti G., Bates M., Park E., Daley J.F., Schlossman S.F. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 1983; 131: 244–250
   PubMed Web of Science ®Google Scholar
• Dorken B., Moller P., Pezzutto A., Schwartz-Albiez R., Moldenhauer G. B2 B-cell antigens: CD19. Leukcocyte Typing IV-White Cell Differentiation Antigens, W. Knapp, B. Dorken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H.A. Stein, E.G.K. von dem Borne. Oxford University Press, Oxford 1989; 34–36
   Google Scholar
• Stamenkovic I., Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr Virus-related cytoplasmic tail. J. Exp. Med. 1988; 168: 1205–1210
   PubMed Web of Science ®Google Scholar
• Tedder T.F., Isaacs C.M. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: A new member of the immunoglobulin super family. J. Immunol. 1989; 143: 712–717
   PubMed Web of Science ®Google Scholar
• Zhou L.-J., Ord D.C., Hughes A.L., Tedder T.F. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes: Conservation of the extensive cytoplasmic domain. J. Immunol. 1991; 147: 1424–1432
   PubMed Web of Science ®Google Scholar
• De Vita V.T., Jr., Jaffe E.S., Mauch P., Longo D.L. Lymphocytic lymphomas. Cancer-Principles & Practice of Oncology, V.T. De, S. Vita, Jr., Hellman, S.A. Rosenberg. Lippincott, Philadelphia 1989; 1741–1798
   Google Scholar
• Verwer B.J.H., Terstappen L. W. M. M. Automatic lineage assignment of acute leukemias by flow cytometry. Cytometry 1993; 14: 862–875
   PubMedGoogle Scholar
• Pontvert-Delucq S., Breton-Gorius J., Schmitt C., Baillou C., Guichard J., Najman A., Lemoine F.M. Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development. Blood 1993; 82: 417–429
   PubMed Web of Science ®Google Scholar
• Harada H., Kawano M.M., Huang N., Hwada Y., Iwato K., Tdnabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 81: 2658–2663
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Muraguchi A., Ledbetter J.A., Kishimosto T., O'Brien R.T., Roloff J.S., Gajl-Peczalska K., Provisor A., Koller B. Biphenotypic leukemic lymphocyte precursors, in CD2+CD19+ acute lymphoblastic leukemia and their putat'ive normal counterparts in human fet al hematopoietic tissues. Blond 1989; 73: 1000–1015
   PubMed Web of Science ®Google Scholar
• Holder M.J., Knox K., Gordon J. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-β, but not cyclosporin A or anti-CD19. block surface immunoglobulin-mediated rescue from apoptosis. Eur. J. Immunol. 1992; 22: 2725–2728
   PubMed Web of Science ®Google Scholar
• Schriever F., Freedman A.S., Freeman G., Messner E., Daley J., Nadler L.M. B22.8 Isolation and phenotypic characterization of follicular dendritic cells from human tonsil. Leucocyte Typing IV-White Cell Differentiation Antigens, W. Knapp, B. Dorken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H.A. Stein, E.G.K. van dem Borne. Oxford University Press, Oxford 1989; 185
   Google Scholar
• Petrasch S., Schmitz J., Perez-Alvarez C., Brittinger G. B22.9 Reactivity of mAb of the B-cell panel with isolated follicular dendritic cells. Leucocyte Typing IV-White Cell Differentiation Antigens, W. Knapp, B. Darken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H.A. Stein, E.G.K. von dem Borne. Oxford University Press, Oxford 1989; 185–187
   Google Scholar
• Uckun F.M., Jaszcz W., Ambrus J.L., Fauci A.S., Gajl-Peczalska K., Song C.W., Wick M.R., Myers D.E., Waddick K., Ledbetter J.A. Detailed studies on expression and function of CD19 surface determinant by using 843 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988; 71: 13–29
   PubMed Web of Science ®Google Scholar
• Perzutto A., Behm F., Callard R.E., Clark E.A., Genetet N., Goodall A.H., Gramatzki M., Hostoffer P., Cooper M.D., Heldrup J., Campana D., Janossy G., Ling N.R., Ledbetter J.A., Ludwig W.D., Pilkington G.R., Steel C.M., Tedder T.F., Wijdenes J., Racadoet E., Darken B. B22.3 Flow cytometry analysis of the B-cell blind panel: Joint report. Leucocyte Typing IV-White Cell Differentiation Antigens, W. Knapp, B. Dorken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H.A. Stein, E.G.K. von dem Borne. Oxford University Press, Oxford 1989; 165–174
   Google Scholar
• De Rossi G., Grossi C., Foa R., Tabilio A., Vegna Lo L., Coco F., Annino L., Camera A., Cascavilla N., Ciolli S.D, El Poeta G., Lisa V., Mandelli F. Immunophenotype of acute lymphoblastic leukemia cells: The experience of the Italian Cooperative Group (Gimema). Leu. Lym. 1993; 9: 221–228
   PubMed Web of Science ®Google Scholar
• Schwonzen M., Pohl C., Steinmetz T., Seckler W., Vetten IB., Thiele J., Wickramanayake D., Diehl V. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: Poor correlation between immunophenotype and cytological/histological classification. Brit. J. Haemat. 1993; 83: 232–2159
   PubMed Web of Science ®Google Scholar
• Robbins B.A., Ellison D.J., Spinosa J.C., Carey C.A., Lukes R.J., Poppema S., Saven A., Piro L.D. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993; 82: 1277–1287
   PubMed Web of Science ®Google Scholar
• Matutes E., Morilla R., Owusu-Ankomah K., Houlihan A., Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994; 83: 1558–1502
   PubMed Web of Science ®Google Scholar
• Kubagawa H., Vogler L.B., Capra J.D., Conrad M.E., Lawton A.R., Cooper M.D. Studies on the clonal origin of mid tiple myeloma. J. Exp. Med. 1979; 150: 792–807
   PubMed Web of Science ®Google Scholar
• Omede P., Boccadoro M., Fusaro A., Gallone G., Pileri A. Multiple myeloma: 'Early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Brit. J. Haemat. 1993; 85: 504–513
   PubMed Web of Science ®Google Scholar
• Corradini P., Boccadoro M., Voena C., Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to Cμ sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas. J. Exp. Med. 1993; 178: 1091–1096
   PubMed Web of Science ®Google Scholar
• Kita K., Nakase K., Miwa H., Masuya M., Nishii K., Morita N., Takakura N., Otsuji A., Shirakawa S., Ueda T., Nasu K., Kyo T., Dohy H., Kamada N. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21) (q22;q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992; 80: 470–477
   PubMed Web of Science ®Google Scholar
• Buccheri V., Matutes E., Dyer M.J.S., Catovsky D. Lineage commitment in hiphenotypic acute leukemia. Leukemia 1993; 7: 919–927
   PubMed Web of Science ®Google Scholar
• Reading C.L., Estely E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L. W. M. M., O'Brien M.C., Baron S., Deisseroth A.B. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993; 81: 3083–3090
   PubMed Web of Science ®Google Scholar
• Kuerbitr S.J., Civin C.I., Krischer J.P., Ravindranath Y., Steuber C.P., Weiinstein H.J., Winick N., Ragab A.H., Gresik M.V., Crist W.M. Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: A Pediatric Oncology Group study. J. Clin. Oncology 1992; 10: 1419–1429
   PubMed Web of Science ®Google Scholar
• Bleyer W.A., Poplack D.G. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin. Oncol. 1985; 12: 13–148
   PubMedGoogle Scholar
• Crist W.M., Grossi C.E., Pullen D.J., Cooper M.D. Immunologic markers in childhood acute lymphocytic leukemia. Semin. Oncology 1985; 12: 105–121
   PubMed Web of Science ®Google Scholar
• Crist W. FA., Carroll A.J., Shuster J.J., Behm F.G., Whitehead M., Vietti T.J., Look A.T., Mahoney D., Ragab A., Pullen D.J., Land V.J. Poor prognosis of children with pre-B acute lymphoblastic leukemia 15 associated with the t(1;19)(q23;p13): A Pediatric Oncology Croup study. Blood 1990; 76: 117–122
   PubMed Web of Science ®Google Scholar
• Borowitz M.J., Hunger S.P., Carroll A.J., Shuster J.J., Pullen D.J., Steuber C.P., Cleary M.L. Predictability of the t(1;19)(q23;pl3) from surface antigen phenotype: Implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: A Pediatric Oncology Group study. Blood 1993; 82: 1086–1091
   PubMed Web of Science ®Google Scholar
• Solary E., Casasnovas R.-O., Campos L., Bene M.-C., Faure G., Maingon P., Falkenrodt A., Lenormand B., Genetet N. The GEIL 1992 Surface markers in adult acute myeloblastic leukemia: Correlation of CD19+, CD34+ and CD14+/DR.- phenotypes with shorter survival. Leukemia, 6: 393–399
   PubMed Web of Science ®Google Scholar
• Smith F.O., Lampkin B.C., Versteeg C., Flowers D.A., Dinndorf P.A., Buckley J.D., Woods W.G., Hammond G.D., Bernstein I.D. Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood 1992; 79: 2415–2422
   PubMed Web of Science ®Google Scholar
• Ball E.D., Davis R.B., Griffin J.D., Mayer R.J., Davey F.R., Arthur D.C., Wurrter-Hill D., Noll W., Elghetany M.T., Allen S.L., Rai K., Lee E.I., Schiffer C.A., Bloomfield C.D. Prognostic value of lymphocyte surface makers in acute myeloid leukemia. Blood 1991; 77: 2242–2250
   PubMed Web of Science ®Google Scholar
• Vuillier F., Claisse J.F., Vaiidenvelde C., Travade P., Magnac C., Chevret S., Desableris B., Binet J.L., Dighiero G. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CDS-CD19 markers and PCR study of gene rearrangements. Len. Lym. 1992; 7: 195–204
   PubMed Web of Science ®Google Scholar
• Keating M.J., O'Brien S., Robertson L., Huh Y., Kantarjian H., Plunkett W. Chronic lymphocytic leukemia—Correlation of response and survival. Leu. Lym. 1993; 11: 167–175, Suppl. 2.
   PubMed Web of Science ®Google Scholar
• Armitage J.O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 1989; 73: 1749–1758
   PubMed Web of Science ®Google Scholar
• Champlin R., Gale R.P. Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 1989; 73: 2051–2066
   PubMed Web of Science ®Google Scholar
• Frei E., III, Antman K., Teicher B., Eder P., Schnipper L. Bone marrow autotransplantation for solid tumors- Prospects. J. Clin. Oncology 1989; 7: 515–526
   PubMed Web of Science ®Google Scholar
• Negrin R.S., Pesando J. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J. Clin. Oncology 1994; 12: 1021–1027
   PubMed Web of Science ®Google Scholar
• Gribben J.G., Freedman A.S., Neuberg D., Roy D.C., Blake K.W., Woo S.D., Grossbard M.L., Rabinowe S.N., Coral F., Freeman G.J., Ritz J., Nadler L.M. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. NEJM 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Gribben J.G., Saporito L., Barber M., Blake K.W., Edwards R.M., Griffin J.D., Freedman A.S., Nadler L.M. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 1992; 80: 1083–1089
   PubMed Web of Science ®Google Scholar
• Rhodes E.G.H., Baker P., Rhodes J.M., Davies J.M., Cawley J.C. Peanut agglutinin in combination with CD19 monoclonal antibody has potential as a purging agent in myeloma. Exp. Hematol. 1991; 19: 833–837
   PubMed Web of Science ®Google Scholar
• Rhodes E.G.H., Baker P.K., Duguid J.K.M., Davies J.M., Cawley J.C. A method for clinical purging of myeloma bone marrow using peanut agglutinin as an anti-plasma cell agent, in combination with CD19 monoclonal antibody. Bone Marrow Transplantation 1992; 10: 485489
   Google Scholar
• Muirhead M., Martin P.J., Torok-Storb B., Uhr J.W., Vitetta E.S. Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood 1983; 62: 327–332
   PubMed Web of Science ®Google Scholar
• Bjorn M.J., Manger R., Sivam G., Morgan A.C., Jr., Torok-Storb B. Selective elimination of breast cancer cells from human bone marrow using an antibody-Pseudomonas exotoxin A conjugate. Cancer Res. 1990; 50: 5992–5996
   PubMed Web of Science ®Google Scholar
• Tondini C., Pap S.A., Hayes D.F., Elias A.D., Kufe D.W. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res. 1990; 50: 1170–1175
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Ramakrishnan S., Houston L.L. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. Cancer Res. 1985; 45: 69–75
   PubMed Web of Science ®Google Scholar
• Vuist W.M.J., Buitenen F.v., De Rie M.A., Hekman A., Rumke P., Melief C.J.M. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. Cancer Res. 1989; 49: 3783–3788
   PubMed Web of Science ®Google Scholar
• Vuist W.M.J., Buitenen F.v., Hekman A., Melief C.J.M. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. Cancer Res. 1990; 50: 5767–5772
   PubMed Web of Science ®Google Scholar
• Anderson P.M., Crist W., Hasz D., Carroll A.J., Myers D.E., Uckun F.M. G19.4(αCD3) × B43(αCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992; 80: 2826–2834
   PubMed Web of Science ®Google Scholar
• Haagen I.A., van de Griend R., Clark M., Geerars A., Bast B., De Cast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bi-specific monoclonal antibody (αCD3/αCD19). Clin. Exp. Immunol. 1992; 90: 368–375
   PubMed Web of Science ®Google Scholar
• Bonardi M.A., Bell A., French R.R., Gromo G., Hamblin T., Modena D., Tutt A.L., Glennie M.J. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int. J. Cancer Supplement 7, 1992; 73–77
   Web of Science ®Google Scholar
• Bonardi M.A., French R.R., Amlot P., Gromo G., Modena D., Glennie M.J. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res. 1993; 53: 3015–3021
   Google Scholar
• Rowland A.J., Pietersz G.A., McKenzie I.F.C. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates. Cancer Immunol. Immunother. 1993; 37: 195–202
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Chelstrom L.M., Irvin J.D., Finnegan D., Gunther R., Young J., Kuebelbeck V., Myers D.E., Houston L.L. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-I murine B-cell leukemia. Blood 1992; 79: 2649–2661
   PubMed Web of Science ®Google Scholar
• Jansen B., Uckun F.M., Jaszcz W.B., Kersey J.H. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CDI9 (B43)-pokeweed antiviral prctein immunotoxin. Cancer Res. 1992; 52: 406–412
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Myers D.E., Irvin J.D., Kuebelbeck V.M., Finnegan D., Chelstrom L.M., Houston L.L. Effects of the inter-molecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin. Leu. Lym. 1993; 9: 459–476
   PubMed Web of Science ®Google Scholar
• Jansen B., Kersey J.H., Jaszcz W.B., Gunther R., Nguyen D.P., Chelstrom L.M., Tuel-Ahlgren L., Uckun F.M. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 1993; 7: 290–297
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Manivel C., Irvin J.D., Myers D.E., Gunther R. Effective immunochemotherapy of CALLA+Cμ+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–3129
   PubMed Web of Science ®Google Scholar
• Ghetie M.-A., May R.D., Till M., Uhr J.W., Ghetie V., Knowles P.P., Relf M., Brown A., Wallace P.M., Janossy G., Amlot P., Vitetta E.S., Thorpe P.E. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 1988; 48: 2610–2617
   PubMed Web of Science ®Google Scholar
• Ghetie M.-A., Tucker K., Richardson J., Uhr J.W., Vitetta E.S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80: 2315–2320
   PubMed Web of Science ®Google Scholar
• Ghetie M.-A., Tucker K., Richardson J., Uhr J.W., Vitetta E.S. The eradication of minimal disease in SCID mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 1994, in press
   Web of Science ®Google Scholar
• Shah S.A., Halloran P.M., Ferris C.A., Levine B.A., Bourret L.A., Goldmacher V.S., Blattler W.A. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 1993; 53: 1360–1367
   PubMed Web of Science ®Google Scholar
• Hekman A., Honselaar A., Vuist W.M.J., Sein J.J., Rodenhuis ten Bokk S., El Huinink W.W., Somers R., Rumke P., Melief C.J.M. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol. Immunother. 1991; 32: 364–372
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Freedman A.S., Ritz J., Coral F., Goldmacher V.S., Eliseo L., Spector N., Dear K., Lambert J.M., Blattler W.A., Taylor J.A., Nadler L.M. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A Phase I trial of daily bolus infusion. Blood 1992; 79: 576–585
   PubMed Web of Science ®Google Scholar
• Grossbard M.L., Gribben J.G., Freedman A.S., Lambert J.M., Kinsella J., Rabinowe S.N., Eliseo L., Taylor J.A., Blattler W.A., Epstein C.L., Nadler L.M. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263–2271
   PubMed Web of Science ®Google Scholar
• Bradbury L.E., Kansas G.S., Levy S., Evans R.L., Tedhr T.F. The CD19/CD21 signal transducing complex of human B lymphocytes includes the Target of Antiproliferative Antibody-1 and Leu-13 molecules. J. Immunol. 1992; 149: 2841–2850
   PubMed Web of Science ®Google Scholar
• Matsumoto A.K., Martin D.R., Carter R.H., Klickstein L.B., Aheam J.M., Fearon D.T. Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes. J. Exp. Med. 1993; 178: 1407–1417
   PubMedGoogle Scholar
• Pesando J.M., Bouchard L.S., McMaster B.E. CD19 is functionally and physically associated with surface immunoglobulin. J. Exp. Med. 1989; 170: 2159–2164
   PubMed Web of Science ®Google Scholar
• Roifman C.M., Ke S. CD19 is a substrate of the antigen receptor-associated protein tyrosine kinase in human B cells. Biochem. Biophys. Res. Comm. 1993; 194: 222–225
   PubMed Web of Science ®Google Scholar
• van Noesel C.J.M., Lankester A.C., van Schijndel G.M.W., van Lier R.A.W. The CR2/CD19 complex on human B cells contains the src-family kinase. Lyn, Int. Immunol. 1993; 5: 699–705
   PubMed Web of Science ®Google Scholar
• Uckun F.M., Burkhardt A.L., Jarvis L., Jun X., Stealey B., Dibirdik I., Myers D.E., Tuel-Ahlgren L., Bolen J.B. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 1993; 268: 21172–21184
   PubMed Web of Science ®Google Scholar
• Chalupny N.J., Kanner S.B., Schieven G.L., Wee S.F., Gilliland L.K., Aruffo A., Ledbetter J.A. Tyrosine phosphorylation of CD19 in pre-B and mature B cells. EMBO J. 1990; 12: 2691–2696
   Google Scholar
• Smith S.H., Rigley K.P., Callard R.E. Activation of human B cells through the CD19 surface antigen results in homotypic adhesion by LFA-1-dependent and independent mechanisms. Immunol. 1991; 73: 293–297
   PubMed Web of Science ®Google Scholar
• Kansas G.S., Tedder T.F. Transmembrane signals generated through MHC class 11, CD19, CD20, CD39, and CD40 antigens induce LFA-I -dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J. Immunol. 1991; 147: 4094–4102
   PubMed Web of Science ®Google Scholar
• Pezzutto A., Dorken B., Rabinovitch P.S., Ledbetter J.A., Moldenhauer G., Clark E.A. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J. Immunol. 1987; 138: 2793–2799
   PubMed Web of Science ®Google Scholar
• Ledbetter I.A., Rabinovitch P.S., June C.H., Song C.W., Clark E.A., Uckun F.M. Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 1897–1901
   PubMed Web of Science ®Google Scholar
• De Rie M.A., Schumacher T.N.M., van Schijndel G.M.W., van Lier R.A.W., Miedema F. Regulatory role of CID 19 molecules in B-cell activation and differentiation. Cell. Immunol. 1989; 118: 368–381
   PubMed Web of Science ®Google Scholar
• Carter R.H., Tuveson D.A., Park D.J., Rhee S.G., Fearon D.T. The CD 19 complex of B lymphocytes: Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J. Immunol. 1991; 147: 3663–3671
   PubMed Web of Science ®Google Scholar
• Barrett T.B., Shu G.L., Draves K.E., Pezzutto A., Clark E.A. Signaling through CD19, Fc receptors or transforming growth factor-β: Each inhibits the activation of resting human B cells differently. Eur. J. Immunol. 1990; 20: 1053–1059
   PubMed Web of Science ®Google Scholar
• Rigley K.P., Callard R.E. Inhibition of B cell proliferation with anti-CD19 monoclonal antibodies: Anti-CD19 antibodies do not interfere with early signaling events triggered by anti-IgM or interleukin 4. Eur. J. Immunol. 1991; 21: 535–540
   PubMed Web of Science ®Google Scholar
• Callard R.E., Rigley K.P., Smith S.H., Thurstan S., Shields J.G. CD19 regulation of human B cell responses: B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used. J. Immunol. 1992; 148: 2983–2987
   PubMed Web of Science ®Google Scholar
• Golay J., Cusmano G., Introna M. Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. J. Immunol. 1992; 149: 300–308
   PubMed Web of Science ®Google Scholar
• Carter R.H., Fearon D.T. CD19: Lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105–107
   PubMed Web of Science ®Google Scholar
• Ghetie M-A., Picker L.J., Richardson J.A., Tucker K., Uhr I.W., Vietta E.S. Anti-CD19 inhibits the growth of human 9-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood 1994; 83: 1329–1336
   PubMed Web of Science ®Google Scholar
• Scheuermann R.H., Racila E., Tucker T.F., Yefenof E., Street N.E., Vitetta E.S., Picker IL.J., Uhr J.W. Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in 9-lineage lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 4048–4052
   PubMed Web of Science ®Google Scholar
• Vitetta E.S., Uhr J.W. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy. Cancer Res. 1994, submitted
   PubMedGoogle Scholar
• Yefenof E., Picker L.J., Scheuermann R.H., Tucker T.F., Vitetta E.S., Uhr J.W. Cancer dormancy: Isolation and characterization of dormant lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 1829–1833
   PubMed Web of Science ®Google Scholar
• Racila E., Scheuermann R., Picker L., Yefenof E., Tucker T., Chang W., Marches R., Street N., Vitetta E.S., Uhr I.W. Tumor dormancy. II. Antibody as an aganist in inducing dormancy of a B cell lymphoma in SCID mice. J. Exp. Med. 1994, Submitted
   Web of Science ®Google Scholar
• Marches R., Scheuermann R.H., Picker L.J., Tucker T.F., Racila E., Street N.E., Shen G., Li J., Wei B., Ilgen A., Vitetta E.S., Uhr J.W. Antibodies against different epitopes on p185erbB-2 cause cell cycle arrest or cell death in human breast cancer cells. Cancer Res. 1994, submitted
   Google Scholar
• Darzynkiewicz Z., Bruno S.D, El Bino G., Corczyca W., Hotz M.A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795–808
   PubMedGoogle Scholar
• Kiesel S., Haas R., Moldenhauer G., Kvalheim G., Pezzutto A., Dorken B. Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobuliin switch variant mediated cytolysis. Leukemia Res. 1987; 11: 1119–1125
   PubMed Web of Science ®Google Scholar
• Kvalheim G., Fodstad O., Pihl A., Nustad K., Pharo A., Ugelstad J., Funderud S. Elimination of B-lymphoma cells from human bone marrow: Model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies. Cancer Res. 1987; 47: 846–851
   PubMed Web of Science ®Google Scholar
• Watanabe M., Pesando J.M., Hakomori S. Effect of liposomes containing sodium butyrate conjugated with anti-CD19 monoclonal antibodies on in vitro and in vivo growth of malignant lymphoma. Cancer Res. 1990; 50: 3245–3248
   PubMed Web of Science ®Google Scholar